Darmani Nissar A
Department of Basic Medical Sciences, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA.
Pharmaceuticals (Basel). 2010 Sep 3;3(9):2930-2955. doi: 10.3390/ph3092930.
Chemotherapy-induced nausea and vomiting (CINV) is a complex pathophysiological condition and consists of two phases. The conventional CINV neurotransmitter hypothesis suggests that the immediate phase is mainly due to release of serotonin (5-HT) from the enterochromaffin cells in the gastrointestinal tract (GIT), while the delayed phase is a consequence of release of substance P (SP) in the brainstem. However, more recent findings argue against this simplistic neurotransmitter and anatomical view of CINV. Revision of the hypothesis advocates a more complex, differential and overlapping involvement of several emetic neurotransmitters/modulators (e.g. dopamine, serotonin, substance P, prostaglandins and related arachidonic acid derived metabolites) in both phases of emesis occurring concomitantly in the brainstem and in the GIT enteric nervous system (ENS) [1]. No single antiemetic is currently available to completely prevent both phases of CINV. The standard antiemetic regimens include a 5-HT₃ antagonist plus dexamethasone for the prevention of acute emetic phase, combined with an NK receptor antagonist (e.g. aprepitant) for the delayed phase. Although NK antagonists behave in animals as broad-spectrum antiemetics against different emetogens including cisplatin-induced acute and delayed vomiting, by themselves they are not very effective against CINV in cancer patients. Cannabinoids such as D⁸-THC also behave as broad-spectrum antiemetics against diverse emetic stimuli as well as being effective against both phases of CINV in animals and patients. Potential side effects may limit the clinical utility of direct-acting cannabinoid agonists which could be avoided by the use of corresponding indirect-acting agonists. Cannabinoids (both phyto-derived and synthetic) behave as agonist antiemetics via the activation of cannabinoid CB₁ receptors in both the brainstem and the ENS emetic loci. An endocannabinoid antiemetic tone may exist since inverse CB₁ agonists (but not the corresponding silent antagonists) cause nausea and vomiting.
化疗引起的恶心和呕吐(CINV)是一种复杂的病理生理状况,包括两个阶段。传统的CINV神经递质假说是,急性期主要是由于胃肠道(GIT)肠嗜铬细胞释放5-羟色胺(5-HT),而延迟期是脑干中P物质(SP)释放的结果。然而,最近的研究结果对这种关于CINV的简单化神经递质和解剖学观点提出了质疑。该假说的修订主张在脑干和GIT肠神经系统(ENS)中同时发生的呕吐的两个阶段,几种催吐神经递质/调节剂(如多巴胺、5-羟色胺、P物质、前列腺素和相关花生四烯酸衍生代谢物)有更复杂、不同且重叠的参与[1]。目前没有单一的止吐药可完全预防CINV的两个阶段。标准的止吐方案包括使用5-HT₃拮抗剂加地塞米松预防急性呕吐期,联合NK受体拮抗剂(如阿瑞匹坦)预防延迟期。尽管NK拮抗剂在动物中对包括顺铂引起的急性和延迟呕吐在内的不同催吐原表现为广谱止吐药,但它们本身对癌症患者的CINV效果不佳。大麻素如D⁸-THC对多种催吐刺激也表现为广谱止吐药,并且对动物和患者的CINV两个阶段都有效。潜在的副作用可能会限制直接作用的大麻素激动剂的临床应用,而使用相应的间接作用激动剂可以避免这种情况。大麻素(植物来源和合成的)通过激活脑干和ENS催吐位点中的大麻素CB₁受体发挥激动剂止吐作用。由于CB₁反向激动剂(而非相应的沉默拮抗剂)会引起恶心和呕吐,因此可能存在内源性大麻素止吐基调。